Life sciences runs on some of the most process-heavy, data-dense workflows in any industry: gross-to-net calculations, government pricing submissions, rebate adjudication, patient access coordination. Each one is rule-bound, auditable and measured — which is precisely what makes them ideal territory for AI done properly.
The mistake is treating AI as a replacement for these processes. The opportunity is instrumentation: models that watch every deduction, every chargeback, every price calculation, and flag the ones a human should look at — before they reach the P&L or an auditor.
Gross-to-net: where the leakage lives
In most GTN operations, chargebacks and rebates are reconciled quarterly — which means leakage compounds for months before anyone sees it. Anomaly-detection models trained on your historical deductions can reconcile daily, flag anomalous claims within hours, and route them to a named owner with the evidence attached. Teams typically recover 1–3 points of margin in the first year from leakage that was always visible in the data, just never at the right time.
Compliance is a feature, not a constraint
AMP, BEST price and FSS calculations leave no room for black boxes. Every AI-assisted number needs an audit trail: which inputs, which rules, which human approved it. That is why we build human-in-the-loop review into the workflow itself — AI reviewers double-check calculations, humans sign off, and the whole chain is logged for audit. GxP and SoX controls are designed in from day one, not bolted on before an inspection.
The result is a process that is simultaneously faster and more defensible — the rare case where innovation and compliance pull in the same direction.